Investigating how antiretroviral therapy affects the risk of oral HPV infection in people with HIV
The role of antiretroviral therapy in susceptibility to oral human papillomavirus (HPV) infection
This study is looking at how taking HIV medication might affect the risk of getting oral HPV in people living with HIV, and it will compare those on treatment to others who are HIV-negative, to help understand how these medications impact oral health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lsu Health Sciences Center NIH-funded |
| Lab location | 1 site (New Orleans, United States) |
| Project ID | NIH-10893234 on NIH RePORTER |
What this research studies
This research examines the relationship between antiretroviral therapy (ART) and the risk of oral human papillomavirus (HPV) infection in individuals living with HIV. It aims to understand how ART may impact the structural integrity of oral mucosal tissue, potentially increasing susceptibility to HPV. The study will compare the prevalence of oral HPV infection in people taking ART for HIV management and those taking it for pre-exposure prophylaxis (PrEP) against a control group of HIV-negative individuals. By analyzing oral mucosal samples, the research seeks to provide insights into the effects of ART on oral health in the context of HPV.
Who could benefit from this research
Good fit: Ideal candidates include individuals living with HIV who are undergoing antiretroviral therapy, as well as those taking ART for pre-exposure prophylaxis.
Not a fit: Patients who are not on antiretroviral therapy or those who do not have any risk factors for HPV infection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and management of oral HPV risks in individuals on antiretroviral therapy.
How similar studies have performed: While the specific approach of this research is novel, prior studies have indicated potential links between ART and increased HPV susceptibility, suggesting a need for further investigation.
Where this research is happening
New Orleans, United States
- Lsu Health Sciences Center — New Orleans, United States (Active)
Researchers
- Principal investigator: Cameron, Jennifer Erin — Lsu Health Sciences Center
- Study coordinator: Cameron, Jennifer Erin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.